DEF: PepGen Inc. Announces 2025 Annual Meeting of Stockholders

PepGen Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 4, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

Summary

• PepGen Inc. is holding its 2025 Annual Meeting of Stockholders on June 4, 2025, virtually via live webcast.
• Stockholders of record as of April 8, 2025, are entitled to vote.
• The meeting will include the election of three Class III directors to serve until the 2028 annual meeting, the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and any other business properly brought before the meeting.
• The board of directors recommends voting FOR the election of the director nominees and FOR the ratification of KPMG LLP's appointment.
• As of April 8, 2025, there were 32,720,943 shares of common stock outstanding, each entitled to one vote.
• The company is an emerging growth company and therefore has certain reduced public company reporting requirements.

Sentiment

Score: 7

Explanation: The document is a standard corporate communication, presenting factual information in a neutral tone. The sentiment is moderately positive as it reflects the company's ongoing corporate governance and compliance activities.

Positives

• The company is taking advantage of SEC rules to furnish proxy materials over the internet, reducing environmental impact and costs.
• The board of directors is committed to ensuring stockholders have the same rights and opportunities to participate as they would at an in-person meeting.
• The audit committee has pre-approval policies and procedures for audit and non-audit services performed by the independent registered public accounting firm.
• The company has adopted a Code of Business Conduct and Ethics applicable to directors, officers, and employees.
• The company has entered into indemnification agreements with its directors and executive officers.
• The company maintains a 401(k) retirement savings plan for its employees, including named executive officers, with a non-elective employer contribution.

Negatives

• Christopher Ashton, Ph.D., resigned from the board of directors, effective September 30, 2024.
• As an emerging growth company, PepGen is permitted to conform with certain reduced public company reporting requirements.

Risks

• The division of the board of directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a change of management or a change in control.
• Risk is inherent with every business, and how well a business manages risk can ultimately determine its success.
• The company faces a number of risks, including the risks more fully discussed in the section titled 'Risk Factors' appearing in our 2024 Annual Report.

Future Outlook

The document outlines the agenda and procedures for the upcoming annual meeting, focusing on electing directors and ratifying the appointment of the independent accounting firm. It does not provide specific forward-looking statements about the company's financial performance or strategic direction beyond the meeting itself.

Industry Context

This proxy statement is a standard document for publicly traded companies, providing stockholders with information necessary to make informed decisions regarding voting on key corporate matters. The items to be voted on, such as director elections and auditor ratification, are typical for annual meetings.

Comparison to Industry Standards

• The structure and content of this proxy statement are consistent with industry standards for publicly traded companies in the United States.
• The director compensation policy, including cash retainers and equity awards, is comparable to those of other biotechnology companies of similar size and stage of development.
• The audit fees paid to KPMG LLP are within the range of fees paid by comparable companies for similar services.
• The corporate governance practices, such as having independent directors and audit, compensation, and nominating committees, align with best practices and regulatory requirements for Nasdaq-listed companies.
• The indemnification agreements with directors and executive officers are standard practice to attract and retain qualified individuals.

Management Changes

Corporate Governance

Related Party Transactions

• License agreement with Oxford University Innovation Limited (OUI) and the Medical Research Council of United Kingdom Research and Innovation (MRC).
• Entities affiliated with RA Capital Management GP, LLC acquired 2,557,593 shares of our common stock in our Follow-on Offering at the purchase price of $10.365 per share and on the same terms and conditions as the other purchasers in the offering.
• Indemnification agreements with Howard Mayer, M.D., and Mitchell Finer, Ph.D. and Lisa Wyman.

Stakeholder Impact

• Stockholders are provided with information to make informed voting decisions.
• Employees are affected by changes in executive compensation and benefit plans.
• The company's performance and governance practices impact investor confidence.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 4, 2025.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K.

Key Dates

Keywords

proxy statement, annual meeting, directors, KPMG, stockholders, governance, compensation, PepGen